# The First-in-human Study of SRN-001 in Healthy Participants

> **NCT05984992** · PHASE1 · COMPLETED · sponsor: **siRNAgen Therapeutics Inc.** · enrollment: 25 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** SRN-001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05984992
- **Lead sponsor:** siRNAgen Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-08
- **Primary completion:** 2024-03-15
- **Final completion:** 2024-09-25
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984992, "The First-in-human Study of SRN-001 in Healthy Participants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05984992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*